Purple Biotech Ltd PPBT
1.34 USD 0.00 (+0.00%)
At closeNov 10, 2026, 4:08 PM EST
1.34 0.00 0.00%
After hours · Nov 10, 4:08 PM ET
1.23 Day range 1.38
0.924 52-week range 8.74
- YTD
- -79.64%
- 1 year
- -84.16%
News
benzinga.com Purple Biotech’s Abstract On IM1240, Lead Tri-Specific Antibody From CAPTN-3 Platform, Accepted For Oral Presentation At 38th EORTC-NCI-AACR Symposium Oral presentation: November 20, 2026 at 15:00 CETREHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company
globenewswire.com Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium Oral presentation: November 20, 2026 at 15:00 CET REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares…
benzinga.com Crude Oil Moves Higher; US Factory Orders Rise In July U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.
benzinga.com Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.
benzinga.com Why Is Purple Biotech Stock Gaining Wednesday? Purple Biotech (PPBT) stock surged premarket after receiving a USPTO patent allowance for its CAPTN-3 tri-specific antibody platform.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS)…
benzinga.com Purple Biotech Issued Patent From U.S. Patent And Trademark Office For Its Application Covering Tri-Specific Antibody Constructs, Models Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity…
globenewswire.com New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies REHOVOT, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the “Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy…
defenseworld.net Financial Review: Ionis Pharmaceuticals (NASDAQ:IONS) & Purple Biotech (NASDAQ:PPBT) Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Purple Biotech (NASDAQ: PPBT - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press…
benzinga.com HC Wainwright & Co. Maintains Buy on Purple Biotech, Lowers Price Target to $17 HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and lowers the price target from $30 to $17.
benzinga.com CORRECTION: Purple Biotech Q2 EPS $(0.41) Beats $(0.98) Estimate Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.98) by 58.16 percent. This is a 89.75 percent increase over losses of…
defenseworld.net Purple Biotech (PPBT) Expected to Announce Quarterly Earnings on Wednesday Purple Biotech (NASDAQ: PPBT - Get Free Report) will likely be announcing its results before the market opens on Wednesday, August 5th. Analysts expect Purple Biotech to announce earnings of ($0.98)…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
globenewswire.com Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Earnings Scheduled For May 15, 2026 
globenewswire.com Purple Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement REHOVOT, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a…
globenewswire.com Purple Biotech Announces CEO Transition Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development
globenewswire.com Purple Biotech Announces Plan to Implement ADS Ratio Change ADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
defenseworld.net Short Interest in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) Expands By 29.9% Purple Biotech Ltd. Sponsored ADR (NASDAQ: PPBT - Get Free Report) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 125,042 shares, an increase…
defenseworld.net Purple Biotech (NASDAQ:PPBT) Shares to Reverse Split on Monday, March 2nd Purple Biotech Ltd. Sponsored ADR (NASDAQ: PPBT) shares are going to reverse split on the morning of Monday, March 2nd. The 1-10 reverse split was announced on Wednesday, February 11th. The number of…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
globenewswire.com Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) --…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
globenewswire.com Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Dow Surges 250 Points; Verizon Posts Mixed Q3 Results - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
globenewswire.com Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first…
globenewswire.com Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification REHOVOT, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek…
globenewswire.com Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants REHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
globenewswire.com Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference REHOVOT, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek…
globenewswire.com Purple Biotech Reports Second Quarter 2025 Financial Results Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG2A, and tumor-associated antigen arms
globenewswire.com Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025 REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek…